ESR1 and cancer: Although requiring additional research concerning the role and mechanism of action of BAZ1B in this context, these data reveal a new therapeutic vulnerability of endocrine therapy-resistant cancer cells, demonstrated by the effects of inhibition of the three factors on ERα expression and multiple key pathways essential for their growth, survival and invasion.